NCT06168929View on ClinicalTrials.gov

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

January 13, 2024

Study Completion Date

January 13, 2024

Conditions
Hyperuricemia
Interventions
DRUG

SHR4640

SHR4640, 2.5mg\*4 - 10mg\*1

DRUG

SHR4640

SHR4640, 10mg\*1 - 2.5mg\*4

Trial Locations (1)

250013

Central Hospital Affilated to Shandong First Medical University, Jinan

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06168929 - Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects | Biotech Hunter | Biotech Hunter